{
    "clinical_study": {
        "@rank": "166428", 
        "acronym": "Lexapro", 
        "arm_group": {
            "arm_group_label": "Escitalopram", 
            "arm_group_type": "Experimental", 
            "description": "Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of long term escitalopram\n      treatment in participants with Major Depressive Disorder (MDD) with associated anxiety\n      symptoms."
        }, 
        "brief_title": "An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Depressive Disorder, Major", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the intervention), single arm,\n      prospective (study following participants forward in time), post-marketing, multi-center\n      (when more than one hospital or medical school team work on a medical research study) study\n      to evaluate the efficacy and safety of escitalopram in participants with MDD with associated\n      anxiety symptoms. The duration of the study will be 24 weeks at a starting dose of\n      escitalopram 10 milligram per day (mg/day). The dose will be flexibly adjusted (maximum 20\n      mg/day) after 2 weeks of treatment depending on Investigator's discretion. The study will\n      consist of 9 visits: Baseline, Week 1, 2, 4, 8, 12, 16, 20 and 24. Assessments of efficacy\n      and safety will be performed at each visit. The primary efficacy evaluation will be done by\n      Montgomery-Asbery Depression Rating Scale (MADRS) and Hamilton Anxiety Scale(HAM-A).\n      Participant's safety will also be monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant must be willing and able to give written informed consent\n\n          -  Participant currently suffering from Major Depressive Disorder (MDD) with anxious\n             symptoms including participant with first MDD episode, and relapsed participant with\n             new episode\n\n          -  Participant with minimum score at baseline of 22 on the Montgomery-Asbery Depression\n             Rating Scale (MADRS) and minimum score at baseline of 14 on Hamilton Anxiety Rating\n             (HAM-A) scales\n\n          -  Female participant must be surgically sterile, or practicing an effective method of\n             birth control before entry and throughout the study\n\n        Exclusion Criteria:\n\n        Participant who has continuously taken psychoactive substances, antidepressants,\n        anxiolytics, monoamine oxidase inhibitors (MAOIs), psychoactive herbal remedies, lithium,\n        electroconvulsive therapy (ECT) carbamazepine in the past 2 weeks before the baseline\n        visit - Participants with MDD, requiring treatment systematically within past 2 months\n        from baseline - Participants who has contraindication  to escitalopram - Participant has\n        primary or comorbid diagnoses of schizophrenia (psychiatric disorder with symptoms of\n        emotional instability, detachment from reality, often with delusions and hallucinations\n        [imagining things], and withdrawal into the self), schizoaffective disorder (a mixed\n        psychiatric disorder relating to a complex psychotic state that has features of both\n        schizophrenia and a mood disorder such as bipolar disorder), bipolar disorder, or dementia\n        (mental decline) - Participant who has a significant risk of suicide on clinical\n        assessment or has made a serious suicide attempt within the past 6-month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "318", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814098", 
            "org_study_id": "CR016381", 
            "secondary_id": "ESCITALDEP4002"
        }, 
        "intervention": {
            "arm_group_label": "Escitalopram", 
            "description": "Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks", 
            "intervention_name": "Escitalopram", 
            "intervention_type": "Drug", 
            "other_name": "Lexapro"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexetimide", 
                "Citalopram"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Depressive Disorder, Major", 
            "Escitalopram", 
            "Lexapro"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "link": {
            "description": "Escitalopram in the Long-term Treatment of Major Depressive Disorder With Associated Anxiety Symptom", 
            "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=2348&filename=CR016381_CSR.pdf"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijng", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Escitalopram in the Long-term Treatment of Major Depressive Disorder With Associated Anxiety Symptom", 
        "overall_official": {
            "affiliation": "Xian-Janssen Pharmaceutical Ltd.", 
            "last_name": "Xian-Janssen Pharmaceutical Ltd., China Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Ethics committee, Shanghai: Mental Health Center", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Remission is defined as MADRS total score =<10 and HAM-A score =<7. MADRS measures depression severity and detects changes due to antidepressant treatment. It consists of 10 items, each scoring from 0 (not present) to 6 (severe). Total score= 0-60. Higher scores indicate more severe condition. HAM-A is 14-item scale measuring anxiety in individuals. Each question reflects a symptom of anxiety (physical and mental symptoms). The answers range from 0 (complete lack of symptom) to 4 (very severe show of anxiety with that symptom). Total score= 0-56. Higher scores indicate a more severe condition.", 
            "measure": "Percentage of Participants With Remission According to Montgomery-Asbery Depression Rating Scale (MADRS) and Hamilton Anxiety Scale (HAM-A)", 
            "safety_issue": "No", 
            "time_frame": "Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814098"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response is defined as having more than or equal to 50 percent decrease from baseline of MADRS total score. The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.", 
                "measure": "Percentage of Participants Showing Response", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.", 
                "measure": "Change From Baseline in MADRS Total Score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.", 
                "measure": "Change From Baseline of Single Rating Item in MADRS Total Score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "The depressive symptoms will be assessed using the 17-item HAMD scale, which provides a total score (0-52) (sum of the scores of all 17 items ). For total score of each item, higher score indicates severity of depressive symptom.", 
                "measure": "Change From Baseline in Hamilton Depression Rating Scale (HAMD)-17 Score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "The HAM-A is a 14-item scale designed to measure anxiety in individuals,which provide a total score of 0-56. Higher scores indicate a more severe condition. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. The answers range from 0 which signifies a complete lack of that symptom to 4, which indicates a very severe show of anxiety with that symptom.", 
                "measure": "Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "The HAM-A is a 14-item scale designed to measure anxiety in individuals,which provide a total score of 0-56. Higher scores indicate a more severe condition. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. The answers range from 0 which signifies a complete lack of that symptom to 4, which indicates a very severe show of anxiety with that symptom.", 
                "measure": "Change From Baseline of Single Rating Item in HAM-A at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\". Higher scores indicate worsening.", 
                "measure": "Change From Baseline in Clinical Global Impression Score (CGI-S) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "The SF-12 consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health Each item is scored into on a 0-100 range. All items are scored so that a high score defines a more favorable health state.", 
                "measure": "Change From Baseline in Short Form-12 (SF-12) Score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "source": "Xian-Janssen Pharmaceutical Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xian-Janssen Pharmaceutical Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}